RESUMO
ABSTRACT: Microblading is a common cosmetic procedure that can modify the appearance of one's eyebrows. Although generally well-tolerated, the procedure can cause a number of dermatologic issues; on rare occasions, granulomatous reactions can manifest. We use this case to highlight a presentation of a nonsarcoidal granulomatous dermatitis and review the literature on granulomatous reactions secondary to microblading. Of the 21 cases included in our review, approximately half (10/21) were diagnosed with foreign-body granulomas and the other half with sarcoidosis (7 of 21 with systemic sarcoidosis and 4 of 21 with cutaneous sarcoidosis). Although microblading remains a commonplace cosmetic technique, it is not without risk. Much like other types of tattoos, microblading can cause granulomatous reactions for which we must be vigilant, and further workup for sarcoidosis might be considered in select patients.
Assuntos
Técnicas Cosméticas , Dermatite , Granuloma de Corpo Estranho , Sarcoidose , Tatuagem , Humanos , Dermatite/complicações , Granuloma de Corpo Estranho/complicações , Sarcoidose/diagnóstico , Tatuagem/efeitos adversos , Técnicas Cosméticas/efeitos adversosRESUMO
We report a case of isolated patchy red hair heterochromia of the scalp in a healthy 6-year-old boy. Isolated patchy scalp hair heterochromia is the presence of two or more colors of hair in the same individual, thought to be due to genetic mosaicism although no specific etiology has been widely accepted. We have outlined a basic approach to diagnosing different types of heterochromia for clinical application.
Assuntos
Doenças do Cabelo , Transtornos da Pigmentação , Criança , Cabelo , Cor de Cabelo/genética , Doenças do Cabelo/diagnóstico , Doenças do Cabelo/genética , Humanos , Masculino , Couro CabeludoRESUMO
Fixed drug eruption (FDE) is a cutaneous drug reaction that tends to recur in the same area (fixed location) upon re-exposure to the offending agent. We present a 48-year-old woman with FDE being treated for metastatic breast cancer with atezolizumab. We believe this is the first reported case of FDE secondary to atezolizumab.